Posts by Adam Lessler
Evidity Health Capital’s Adam Lessler, MD named Partner
NEW YORK and MIAMI, July 5, 2023 Adam Lessler, MD of Evidity Health Capital has recently been named Partner and appointed to the firm’s Management Committee. Adam will continue to oversee Evidity’s investment sourcing and evaluation efforts while taking on additional leadership roles. Evidity is a late-stage venture capital and growth equity firm investing in medtech companies that address…
Read MoreAugmedics raises $82.5 million to accelerate adoption of augmented reality spine surgery
CPMG and Evidity Health Capital join syndicate of US and Israeli investors Augmedics also marks 4,000-patient milestone with xvision AR surgery platform June 27, 2023 08:15 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Augmedics, a pioneer in augmented reality (AR) surgical navigation, today announced the successful close of an $82.5 million Series D financing. The round was…
Read MoreSonde Health Raises $19.25 Million Series B to Build the Next Generation of Voice-Based Health Monitoring
AI vocal biomarker company will use funding to accelerate its commercial growth, expand its platform into new health conditions, and enter new geographies BOSTON — Dec. 8, 2022 Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, has raised a $19.25 million Series B investment round led by Partners Investment,…
Read MoreBD, Magnolia Medical Technologies Announce Commercial Collaboration to Help Reduce Blood Culture Contamination and Improve Testing Accuracy
FRANKLIN LAKES, N.J. (October 18, 2022) –BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes. Under the agreement, BD and Magnolia Medical…
Read MoreDigital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol “AKLI” on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline BOSTON, Mass. & PALO ALTO, Calif. – August 19, 2022 – Akili, a leading digital…
Read MoreEndoGastric Solutions, Inc.® Announces TIF® Procedure Included in New American Gastroenterology Association (AGA) Clinical Practice Update and American College of Gastroenterology (ACG) Guideline
— Leading Gastroenterology Experts Recommend Transoral Incisionless Fundoplication (TIF) for Select Patients with Gastroesophageal Reflux Disease (GERD) — August 09, 2022 09:00 AM Eastern Daylight Time REDMOND, Wa.–(BUSINESS WIRE)–EndoGastric Solutions, Inc.® today announced that the American Gastroenterology Association retired their 2008 guidelines, Management of Gastroesophageal Reflux Disease and released a Clinical Practice Update (CPU), which includes the…
Read MoreMagnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc.
Jury concludes that Kurin used Magnolia Medical’s patented Initial Specimen Diversion Device® technology without permission Seattle, WA, July 29, 2022 – A jury for the U.S. District Court of Delaware delivered two unanimous verdicts this week in favor of Magnolia Medical Technologies, Inc. (“Magnolia Medical”) in a lawsuit against Kurin, Inc., (“Kurin”) regarding the unlawful use…
Read MoreAcuFocus Announces FDA Approval for the IC-8® Apthera™ Intraocular Lens, the First and Only Small Aperture Lens for Cataract Surgery
IRVINE, Calif., July 25, 2022 — AcuFocus, Inc., a privately held ophthalmic medical device company, today announced U.S. Food and Drug Administration (FDA) approval for its breakthrough IC-8® Apthera™ intraocular lens (IOL) for the treatment of cataracts. The Apthera IOL is the first and only non-toric extended depth of focus IOL approved for the 82% of cataract patients who have as…
Read MorePreludeDxTM Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio
Evidity Health Capital to Join Board of Directors LAGUNA HILLS, Calif., March 22, 2022 /PRNewswire/– Prelude Corporation (PreludeDxTM), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors. Alejandro Sanchez,…
Read MoreAkili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
Akili’s leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases,…
Read More